Pancreatic Cancer Research

ResearcherIndiana University HealthNo recent work listed

Safi Shahda

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5091389881. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 5 papers · 2019: 3 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper

Papers 17

  1. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. Co-author DOI 10.1002/jcsm.12998↗
  2. Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. Co-author DOI 10.3390/cancers13081975↗
  3. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated … Co-author DOI 10.1007/s10637-019-00824-1↗
  4. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0489↗
  5. Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform. First author DOI 10.3390/cancers12123787↗
  6. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Co-author DOI 10.1002/jcsm.12461↗
  7. Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. Last author DOI 10.1016/j.gie.2018.09.007↗
  8. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. Last author DOI 10.1186/s12885-019-5630-4↗
  9. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. First author DOI 10.1002/jcsm.12307↗
  10. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancrea… Last author DOI 10.1097/coc.0000000000000409↗
  11. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Co-author DOI 10.1158/1078-0432.ccr-18-1472↗
  12. Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. Co-author DOI 10.1200/po.17.00087↗
  13. Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Co-author DOI 10.3390/cancers10110403↗
  14. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11985↗
  15. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Co-author DOI 10.1158/1535-7163.mct-16-0253↗
  16. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic ca… Co-author DOI 10.1016/j.ijrobp.2014.02.024↗
  17. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. Co-author DOI 10.1371/journal.pone.0047462↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bert H. O’Neil · 8 shared papers, 2017–2020 · strength 0.77
  2. Teresa A Zimmers · 5 shared papers, 2018–2022 · strength 0.53
  3. Yunlong Liu · 4 shared papers, 2018–2022 · strength 0.41
  4. Amikar Sehdev · 4 shared papers, 2017–2019 · strength 0.39
  5. Michael Garrett House · 4 shared papers, 2018–2021 · strength 0.37
  6. Ashok Narasimhan · 3 shared papers, 2020–2022 · strength 0.37
  7. Xiaoling Zhong · 3 shared papers, 2019–2022 · strength 0.33
  8. Nicholas Joseph Zyromski · 4 shared papers, 2016–2021 · strength 0.32
  9. Olumide B. Gbolahan · 3 shared papers, 2018–2019 · strength 0.30
  10. Joshua K. Kays · 3 shared papers, 2018–2021 · strength 0.30
  11. Efrat Dotan · 2 shared papers, 2020 · strength 0.20
  12. Heinz‐Josef Lenz · 2 shared papers, 2020 · strength 0.20
  13. Dana Backlund Cardin · 2 shared papers, 2020 · strength 0.20
  14. Steven J. Cohen · 2 shared papers, 2020 · strength 0.20
  15. Wells A. Messersmith · 2 shared papers, 2020 · strength 0.20
  16. Eugene P. Ceppa · 2 shared papers, 2019–2021 · strength 0.18
  17. Christian Max Schmidt · 2 shared papers, 2019–2021 · strength 0.18
  18. Kumaresan Sandrasegaran · 2 shared papers, 2014–2019 · strength 0.13
  19. John M. DeWitt · 2 shared papers, 2014–2019 · strength 0.13
  20. Lijun Cheng · 1 shared paper, 2020 · strength 0.11
  21. Sarah Lindsey Davis · 1 shared paper, 2020 · strength 0.11
  22. Jordan D. Berlin · 1 shared paper, 2020 · strength 0.11
  23. Hai Salfity · 1 shared paper, 2018 · strength 0.10
  24. Neda Hashemi‐Sadraei · 1 shared paper, 2018 · strength 0.10
  25. Igor A. Astsaturov · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.